The BRAINTEASER Community of Practice shares the most recent advances in the applicability of new technologies, data sources, big data, and AI-based resources in novel treatments, clinical trials, and digital solutions for MS/ALS management.
The life sciences sector is beginning to experience the transformative effects of AI, with numerous applications offering clinical, operational, and medical advantages. Unlike other industries, life sciences face the unique challenge of safeguarding patient safety and privacy. This has led to heightened regulatory scrutiny regarding the development, validation, and implementation of AI technology in this field.
In this environment, the AI Task Force, initiated by the New Technologies Working Group of EUCROF and the eClinical Forum, aims to monitor the evolution of AI technologies and development of related regulations in life sciences and address relevant topics that are of major interest for clinical research.
The white paper “AI state-of-play around clinical research” provides information about the state-of-play of artificial intelligence (AI) and machine learning (ML) for clinical research.
The state-of-the-art of AI in clinical research is presented in four sections, focused on the following topics:
- An overview of the status of regulations in the United States, Europe, Asia and the rest of the world
- A review of major use cases for the domain
- Recommendations for best practices in development and validation of AI in clinical research
- A statement of this task force’s current positions and future work
